HIV的抗逆转录病毒治疗:我们应该检测谁,我们应该治疗谁?
Anti-retroviral therapy for HIV: who should we test and who should we treat?
摘要:
在大多数国家,CD 4+细胞计数仍然被用来决定何时开始对艾滋病毒阳性者进行抗逆转录病毒治疗。然而,由于历史原因,任意选择了各种CD 4+阈值,200、350或500/ \muL。在这里,我们考虑了最佳的CD 4+阈值,生活在博茨瓦纳,南非和津巴布韦的无症状艾滋病毒阳性者应该根据他们的预后开始治疗,考虑他们的CD 4+细胞计数或病毒载量。我们还研究了最佳间隔,人们应该重新测试,如果他们是艾滋病毒阴性。这一分析表明,虽然使用CD 4+细胞计数或病毒载量测试可能有助于在流行病开始时决定如何对患者进行分类治疗,但情况已不再如此,可能只有15至25岁的患者除外。为了不对个别病人造成伤害,一旦发现艾滋病毒呈阳性,每个人都应该开始接受抗逆转录病毒治疗。
英文摘要:
In most countries CD4+ cell counts are still used for deciding when to start HIV-positive people on anti-retroviral therapy. However, various CD4+ thresholds, 200, 350 or 500/\muL, are chosen arbitrarily and for historical reasons. Here we consider the optimal CD4+ threshold at which asymptomatic HIV-positive people living in Botswana, South Africa and Zimbabwe should start treatment depending on their prognosis given their CD4+ cell counts or viral load. We also examine the optimal interval at which people should be retested if they are HIV-negative. This analysis shows that while the use of CD4+ cell counts or viral load tests could have been useful in deciding how to triage patients for treatment at the start of the epidemic this is no longer the case except possibly for those aged about 15 to 25 years. In order not to do harm to individual patients everyone should be started on ART as soon as they are found to be HIV-positive.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。